BianoGMP GmbH
Dr. Tobias Pöhlmann
Ronneburger Straße 74
07546 Gera

Phone: +49 365 77347180




BianoScience offers its extensive experience in molecular biology as service for customer projects. Projects could include optimisation of oligonucleotide delivery in vitro, in vivo biodistribution studies, gene and protein expression as well as histology studies. Special Know how exists regarding:

• Label-free in vivo detection and quantification of oligonucleotides
• Biodistribution studies of RNAi and antisense oligos
• siRNA sequence optimisation
• Optimisation of siRNA delivery
• Gene silencing analyses on mRNA and protein level
• Toxicity studies
• miRNA quantification
• qPCR optimisation

Please contact us for your special request and pricing.

Peptide-siRNA Prodrug - a technology to minimize oligo-induced side effects.

Challenges of therapeutic oligonucleotides
Oligonucleotides have a high therapeutic potential for the treatment of various diseases including cancer and metabolic diseases. The major hurdle of oligonucleotide applications is their intracellular delivery after systemic in vivo application. By using particle based delivery, most of the oligo drugs were delivered into the liver, whereas only partial amounts arrive cancerous tissue. Overdosing in order to reach peripheral (tumor) tissue does induce side effects in the liver and often stimulates the immune system. 

Peptide-siRNA prodrug
BianoScience Peptide-siRNA prodrug approach aimes to reduce these side effects. Based on covalently bound peptides on the 5`antisense strand, the siRNA is applied as an inactive prodrug. Since the peptide contains a cleavage side for specific proteases expressed in the target tissue, siRNA-prodrug is specifically cleaved and activated. On this bases, side effects (especially in the liver) can be massively reduced leading to specific effecs in the target tissue and offering the possibility to increase dosing/side effects ratio.

BianoScience` drug pipeline
Based on the Peptide-siRNA prodrug approach, BianoScience devellops drug candidates to treat Triple-Negative Mammary Cancer with the focus on liver metastases. Intensive animal experiments showed great tolerability and activity of the drug compounds using lipid nanoparticle based delivery strategy. Recent activities aim to optimise delivery and formulation of the oligonucleotide drug compounds, GMP production and start of the clinical phase-1/2a.


Copyright© BianoGMP GmbH

Lab in Gera

BianoGMP GmbH
Ronneburger Straße 74
07546 Gera | Germany

Phone: +49 365 77347180
Manage your consents